{"url_path":"/sec/ptpi/8-k/2026-06-05/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers;","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-05","source_url":"https://www.sec.gov/Archives/edgar/data/1815903/0001104659-26-071027-index.html","accession_number":"0001104659-26-071027","cik":"0001815903","ticker":"PTPI","issuer_name":"Petros Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1815903/0001104659-26-071027-index.html","primary_entity_key":"0001815903","primary_entity_name":"Petros Pharmaceuticals, Inc."},"word_count":267,"has_tables":true,"body_markdown":"**Item 5.02 Departure of Directors or Certain Officers;\nElection of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**\n\n** **\n\nOn\nJune 5, 2026, the Board of Directors (the “Board”) of Petros Pharmaceuticals, Inc. (the “Company”) approved grants,\neffective as of June 5, 2026 (the “Grant Date”), to each of (i) Joshua Silverman, the Company’s Chairman of the Board,\n(ii) Bruce Bernstein, a director of the Company, (iii) Fady Boctor, President and Chief Commercial Officer of the Company, and (iv) Wayne\nWalker, a director of the Company, of an aggregate of 7,000,000 restricted shares of the Company’s common stock (“Restricted\nShares”), par value $0.0001 per share, consisting of: 4,375,000 Restricted Shares to Mr. Silverman, 1,875,000 Restricted Shares\nto Mr. Bernstein, 375,000 Restricted Shares to Mr. Boctor and 375,000 Restricted Shares to Mr. Walker (collectively, the “RSA Awards”).\n50% of each RSA Award vested on the Grant Date and the remaining 50% will vest on the six-month anniversary of the Grant Date, provided\nthat the respective director or officer is providing services to the Company on such vesting date. The RSA Awards were issued outside\nof the Company’s Amended and Restated 2020 Omnibus Incentive Compensation Plan, as amended, and are subject to the terms and conditions\nof the Company’s form of Restricted Stock Award Agreement. \n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned\nhereunto duly authorized.\n\n \n\n \n**Petros pharmaceuticals, Inc****.**\n\n \n \n \n\nDate: June 5, 2026\nBy:\n*/s/ Fady Boctor*\n\n \nName:\nFady Boctor\n\n \nTitle:\nPresident and Chief Commercial Officer"}